Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma

Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma

NCT01689870 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma

NCT01944709 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

NCT05625399 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes

NCT02310451 ·Status: COMPLETED ·Phase: NA

Inducing Systemic Immunity and Regressions in Metastatic Melanoma

NCT02350972 ·Status: COMPLETED ·Phase: PHASE1

CP-461 in the Treatment of Patients With Advanced Melanoma

NCT00060710 ·Status: TERMINATED ·Phase: PHASE2

Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

NCT04526730 ·Status: COMPLETED ·Phase: PHASE2

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

NCT05912244 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

NCT01127451 ·Status: COMPLETED ·Phase: PHASE2

Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions

NCT02862145 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

NCT04562129 ·Status: RECRUITING ·Phase: PHASE2

Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma

NCT02235701 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma

NCT00050102 ·Status: COMPLETED ·Phase: PHASE2

A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma

NCT00942162 ·Status: COMPLETED ·Phase: PHASE2

Taxoprexin® Treatment for Advanced Eye Melanoma

NCT00244816 ·Status: COMPLETED ·Phase: PHASE2

Intratumoral Injections of LL37 for Melanoma

NCT02225366 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox

NCT02009384 ·Status: TERMINATED ·Phase: PHASE2

A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma

NCT01009775 ·Status: COMPLETED ·Phase: PHASE2

mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma

NCT01676779 ·Status: COMPLETED ·Phase: PHASE2

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

NCT00246012 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

NCT02009397 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

NCT04091750 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

NCT00324155 ·Status: COMPLETED ·Phase: PHASE3

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

NCT02366195 ·Status: COMPLETED ·Phase: PHASE2

Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma

NCT00623402 ·Status: COMPLETED ·Phase: PHASE2